Drugs and Licensing - Drug Discovery Digest

Investors put $400M into biotech licensing obesity drugs from China

BioPharma Drive: Drug Pricing

MAY 16, 2024

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

Licensing

Licensing Licensing Drugs Pharmaceuticals

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

BioPharma Drive: Drug Pricing

AUGUST 6, 2024

Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

Licensing

Licensing Licensing Drugs

Takeda pays $300M to license Protagonist drug for blood disorder

BioPharma Drive: Drug Pricing

FEBRUARY 1, 2024

The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.

Licensing

Licensing Licensing Production Drugs

GSK to pay $300M to license drug it sees as potential lupus treatment

BioPharma Drive: Drug Pricing

OCTOBER 29, 2024

The licensing deal with China’s Chimagen Biosciences is the latest example of drugmaker interest in exploring the potential of “T cell engagers” in autoimmune disease.

Licensing

Licensing Licensing Treatment Disease

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

BioPharma Drive: Drug Pricing

NOVEMBER 19, 2024

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.

Licensing

Licensing Licensing FDA Drugs

Gilead bets on Xilio cancer drug as biotech restructures

BioPharma Drive: Drug Pricing

MARCH 28, 2024

Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

Licensing

Licensing Licensing Drugs

Novartis wagers billions of dollars on PTC Huntington’s drug

BioPharma Drive: Drug Pricing

DECEMBER 2, 2024

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.

Licensing

Licensing Licensing Drugs

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

BioPharma Drive: Drug Pricing

MARCH 3, 2025

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing

Licensing Licensing Drug Development Drugs

FTC, in unusual move, leads Sanofi to terminate a drug research deal

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Drug Research

Drug Research Licensing Licensing Research

Benefits of Drug Patent Licensing Agreements

Drug Patent Watch

JULY 30, 2024

The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…

Licensing

Licensing Licensing Pharmaceuticals Drugs

Verdiva starts up with $411M and a portfolio of obesity drugs from China

BioPharma Drive: Drug Pricing

JANUARY 9, 2025

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

Licensing

Licensing Licensing Therapies Drugs

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Licensing

Licensing Licensing Drugs Biosimilars

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug

BioPharma Drive: Drug Pricing

OCTOBER 18, 2024

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

Licensing

Licensing Licensing Regulations Drugs

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy. Novo will pay $200 million to gain control of the protein manufacturing factory.

Licensing

Licensing Licensing Drugs Therapies

Gilead agrees to license new HIV drug in low-income countries

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.

Licensing

Licensing Licensing Disease Drugs

Treatments for poxviruses -- including those causing mpox and smallpox -- may already exist in licensed drugs

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing

Licensing Licensing Treatment Virus

Roivant reveals positive immune drug data, share buyback plans

BioPharma Drive: Drug Pricing

APRIL 2, 2024

A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

Licensing

Licensing Licensing Drugs

AbbVie gets into obesity with $350M deal for once-weekly shot

BioPharma Drive: Drug Pricing

MARCH 3, 2025

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Licensing

Licensing Licensing Therapies Drugs

Royalty Pharma pays startup $525M for stake in Sanofi MS drug

BioPharma Drive: Drug Pricing

MAY 9, 2024

The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

Licensing

Licensing Licensing Drugs

A venture firm breathes new life into an old NGM drug

BioPharma Drive: Drug Pricing

DECEMBER 19, 2024

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.

Licensing

Licensing Licensing Drugs

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

BioPharma Drive: Drug Pricing

JUNE 21, 2024

Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead. A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study.

Drug Development

Drug Development Licensing Licensing Drugs

Takeda secures FDA approval for colon cancer drug

BioPharma Drive: Drug Pricing

NOVEMBER 9, 2023

The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.

FDA Approval

FDA Approval Licensing Licensing FDA

Neurocrine scores surprise win with depression drug

BioPharma Drive: Drug Pricing

APRIL 23, 2024

Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.

Licensing

Licensing Licensing Drugs

TG shares tumble following licensing deal for MS drug

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing

Licensing Licensing Production Marketing

AbbVie joins in latest gastrointestinal drug chase

BioPharma Drive: Drug Pricing

JUNE 14, 2024

Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.

Licensing

Licensing Licensing Drugs

Viking says biopsy data confirm MASH drug’s benefit

BioPharma Drive: Drug Pricing

JUNE 4, 2024

The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

Licensing

Licensing Licensing Treatment Disease

Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.

BioPharma Drive: Drug Pricing

JUNE 18, 2024

With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.

Licensing

Licensing Licensing Drugs

Leqembi sales inch higher; Spark’s pivot leads to layoffs

BioPharma Drive: Drug Pricing

JULY 12, 2024

Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.

Licensing

Licensing Licensing Drugs

Lilly partners with AI specialist Insitro to develop metabolic medicines

BioPharma Drive: Drug Pricing

OCTOBER 9, 2024

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.

Licensing

Licensing Licensing Drugs

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

BioPharma Drive: Drug Pricing

MARCH 3, 2025

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to treat polycythemia vera.

Licensing

Licensing Licensing Drugs

Sarepta rebuilds drug pipeline with Arrowhead deal

BioPharma Drive: Drug Pricing

NOVEMBER 27, 2024

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.

Licensing

Licensing Licensing Drugs Research

LianBio to shut down, return cash to investors

BioPharma Drive: Drug Pricing

FEBRUARY 14, 2024

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

Licensing

Licensing Licensing Marketing Drugs

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

Drug Discovery Today

JANUARY 26, 2022

a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. Saffron Walden, 26th January 2022 / Domainex Ltd.,

Licensing

Licensing Licensing Science Research

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

BioPharma Drive: Drug Pricing

DECEMBER 18, 2024

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

Licensing

Licensing Licensing Drug Development Drugs

Merck allies with Daiichi Sankyo in major bet on antibody cancer drugs

BioPharma Drive: Drug Pricing

OCTOBER 20, 2023

The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.

Licensing

Licensing Licensing Pharmaceuticals Drugs

Bristol Myers licenses Prothena, Evotec brain drugs, inching back into neuroscience

BioPharma Drive: Drug Pricing

JULY 11, 2023

The pharma, which had largely exited the field several years ago, will pay nearly $100 million combined to the two biotechs for rights to several experimental candidates.

Licensing

Licensing Licensing Drugs

Recursion’s Chris Gibson on AI in biotech, competition and ‘virtuous cycles’

BioPharma Drive: Drug Pricing

JANUARY 12, 2024

Showing reporters and industry veterans a demonstration of its new drug development software, Recursion said at J.P. Morgan it is now licensing its work to buyers.

Licensing

Licensing Licensing Drug Development Drugs

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

BioPharma Drive: Drug Pricing

AUGUST 20, 2024

In addition to new stock offerings, this week saw Merck license an antibody drug conjugate and BARDA further work trying to innovate remote clinical trials.

Clinical Trials

Clinical Trials Licensing Licensing Trials

New drug triggers rapid cell death in cancer models

Broad Institute

OCTOBER 29, 2024

New drug triggers rapid cell death in cancer models By Karen Zusi-Tran October 29, 2024 Breadcrumb Home New drug triggers rapid cell death in cancer models BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models. The result was the compound named BRD-810.

Drugs

Drugs Small Molecule Pharmacokinetics Clinical Trials

CDD Includes Industry-Leading IUPAC Naming Technologies From iChemLabs Directly Within CDD Vault

Collaborative Drug

JUNE 21, 2024

Burlingame, CA, June 21, 2024 — Collaborative Drug Discovery (CDD), a leading provider of data management solutions for the pharmaceutical and biotechnology industries, is pleased to announce the integration of iChemLabs' industry-leading IUPAC naming technologies into CDD Vault.

Licensing

Licensing Licensing Pharmaceuticals Drugs

What you should know about the FDA’s Biological License Application Process

Reprocell

SEPTEMBER 19, 2024

The biological license application (BLA) is one of the many requests for marketing approval received by the FDA. Unlike the New Drug Application (NDA) which is usually the go-to submission for chemically synthesized, low molecular weight drugs BLAs grant sponsors the ability to introduce Biologics into interstate commerce.

Licensing

Licensing Licensing Regulations FDA

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Drug Patent Watch

OCTOBER 12, 2021

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.

Production

Production Pharmaceuticals Licensing Licensing

Common Drugs with Effective Off-Label Uses

Drug Patent Watch

JULY 13, 2020

Mudawi in the Journal of Pharmaceutical Research International under the terms of the Creative Commons Attribution License.…. The post Common Drugs with Effective Off-Label Uses appeared first on DrugPatentWatch - Make Better Decisions. This article was originally published by Mohammed M. Alshehri and Mahmoud M.

Licensing

Licensing Licensing Drugs International

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target with Sanofi’s drug discovery programs to move forward the generation of biologics.

Drug Discovery Today

NOVEMBER 11, 2022

Stockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.

Licensing

Licensing Licensing Drugs Research

Investors put $400M into biotech licensing obesity drugs from China

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

Trending Sources

Takeda pays $300M to license Protagonist drug for blood disorder

GSK to pay $300M to license drug it sees as potential lupus treatment

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

Gilead bets on Xilio cancer drug as biotech restructures

Novartis wagers billions of dollars on PTC Huntington’s drug

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

FTC, in unusual move, leads Sanofi to terminate a drug research deal

Benefits of Drug Patent Licensing Agreements

Verdiva starts up with $411M and a portfolio of obesity drugs from China

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug

Novavax sells Czech plant to Novo; Relay licenses out a cancer drug

Gilead agrees to license new HIV drug in low-income countries

Treatments for poxviruses -- including those causing mpox and smallpox -- may already exist in licensed drugs

Roivant reveals positive immune drug data, share buyback plans

AbbVie gets into obesity with $350M deal for once-weekly shot

Royalty Pharma pays startup $525M for stake in Sanofi MS drug

A venture firm breathes new life into an old NGM drug

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

Takeda secures FDA approval for colon cancer drug

Neurocrine scores surprise win with depression drug

TG shares tumble following licensing deal for MS drug

AbbVie joins in latest gastrointestinal drug chase

Viking says biopsy data confirm MASH drug’s benefit

Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.

Leqembi sales inch higher; Spark’s pivot leads to layoffs

Lilly partners with AI specialist Insitro to develop metabolic medicines

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Sarepta rebuilds drug pipeline with Arrowhead deal

LianBio to shut down, return cash to investors

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

Merck allies with Daiichi Sankyo in major bet on antibody cancer drugs

Bristol Myers licenses Prothena, Evotec brain drugs, inching back into neuroscience

Recursion’s Chris Gibson on AI in biotech, competition and ‘virtuous cycles’

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

New drug triggers rapid cell death in cancer models

CDD Includes Industry-Leading IUPAC Naming Technologies From iChemLabs Directly Within CDD Vault

What you should know about the FDA’s Biological License Application Process

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Common Drugs with Effective Off-Label Uses

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target with Sanofi’s drug discovery programs to move forward the generation of biologics.

Stay Connected